Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| Epizyme, Inc. | 2,825,396 | reported | 26 Aug 2014 | tx 10−566,666 |
| EnteroMedics Inc | 2,386,980 | reported | 14 Dec 2010 | tx 8+5,026,016−1,626,016 |
| MADRIGAL PHARMACEUTICALS, INC. | 1,510,521 | reported | 03 Dec 2021 | tx 6−1,147,709 |
| Kezar Life Sciences, Inc. | 472,229 | reported | 25 Jun 2018 | tx 3+622,229−472,229 |
| HYPERION THERAPEUTICS INC | 39,560 | reported | 19 Jul 2013 | tx 6−95,903 |
| NEVRO CORP | 36,403 | reported | 08 Jun 2015 | tx 2−491,835 |
| CORAUTUS GENETICS INC | 35,676 | reported | 08 Aug 2007 | tx 12+12,459,409 |
| Enliven Therapeutics, Inc. | 15,457 | reported | 16 Mar 2020 | tx 9+718,837−4,430,654 |
| NEORX CORP | 3,189 | reported | 29 Aug 2007 | tx 6+4,938 |
| Xilio Therapeutics, Inc. | 0 | reported | 26 Oct 2021 | tx 5+1,129,490−7,761,407 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 03 Dec 2021 | OTHER | MADRIGAL PHARMACEUTICALS, INC. | 24,172 | 0.00 USD | |
| 03 Dec 2021 | OTHER | MADRIGAL PHARMACEUTICALS, INC. | 750,270 | 0.00 USD | |
| 03 Dec 2021 | OTHER | MADRIGAL PHARMACEUTICALS, INC. | 49,730 | 0.00 USD | |
| 26 Oct 2021 | CONVERSION | Xilio Therapeutics, Inc. | 151,294 | — | |
| 26 Oct 2021 | CONVERSION | Xilio Therapeutics, Inc. | 665,696 | — | |
| 26 Oct 2021 | PURCHASE | Xilio Therapeutics, Inc. | 312,500 | 16.00 USD | first after silence |
| 26 Oct 2021 | CONVERSION | Xilio Therapeutics, Inc. | 1,437,297 | — | deriv |
| 26 Oct 2021 | CONVERSION | Xilio Therapeutics, Inc. | 6,324,110 | — | deriv |
| 01 Dec 2020 | OTHER | MADRIGAL PHARMACEUTICALS, INC. | 43,537 | 0.00 USD | |
| 16 Mar 2020 | CONVERSION | Enliven Therapeutics, Inc. | 690,232 | — | |
| 16 Mar 2020 | CONVERSION | Enliven Therapeutics, Inc. | 13,148 | — | |
| 16 Mar 2020 | GRANT_AWARD | Enliven Therapeutics, Inc. | 15,457 | 0.00 USD | deriv |
| 16 Mar 2020 | CONVERSION | Enliven Therapeutics, Inc. | 16,103 | — | deriv |
| 16 Mar 2020 | CONVERSION | Enliven Therapeutics, Inc. | 845,008 | — | deriv |
| 16 Mar 2020 | CONVERSION | Enliven Therapeutics, Inc. | 61,378 | — | deriv |
| 16 Mar 2020 | CONVERSION | Enliven Therapeutics, Inc. | 3,220,915 | — | deriv |
| 16 Mar 2020 | CONVERSION | Enliven Therapeutics, Inc. | 5,372 | — | deriv |
| 16 Mar 2020 | CONVERSION | Enliven Therapeutics, Inc. | 281,878 | — | deriv |
| 25 Jun 2018 | CONVERSION | Kezar Life Sciences, Inc. | 472,229 | — | |
| 25 Jun 2018 | PURCHASE | Kezar Life Sciences, Inc. | 150,000 | 15.00 USD | first after silence |
| 25 Jun 2018 | CONVERSION | Kezar Life Sciences, Inc. | 472,229 | — | deriv |
| 11 Jun 2018 | SALE | MADRIGAL PHARMACEUTICALS, INC. | 274,092 | 287.46 USD | |
| 11 Jun 2018 | SALE | MADRIGAL PHARMACEUTICALS, INC. | 5,908 | 287.46 USD | |
| 08 Jun 2015 | SALE | NEVRO CORP | 481,457 | 47.94 USD | |
| 08 Jun 2015 | SALE | NEVRO CORP | 10,378 | 47.94 USD |
3 purchases reported after at least 12 months of silence — most recent on 26 Oct 2021.